Cure My Disease

Don't miss your cure!

 Log in / Sign up

Why does cervical cancer persist despite prevention tools? a study seeks answers

NCT ID NCT04947605

Knowledge-focused Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

Researchers are collecting detailed information from 524 women with cervical cancer across Latin America to understand why the disease remains common despite effective prevention tools. The study will document tumor types and cancer stages at diagnosis. The goal is to build a solid foundation for national and regional programs to improve cervical cancer prevention and treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide a clearer picture of cervical cancer in Latin America, helping design better prevention and treatment programs tailored to the region.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. The findings depend on the quality and completeness of medical records from many different sites.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

524 people

The number who actually took part.

Started

Nov 2021

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Data from approximately 482 patients are planned to be collected in 7 (seven) countries in Latin America. Enrollment period for data collection is planned to be 18 months and follow-up data will be recorded for 5 years. Patients will receive treatment and clinical assessments for cervical cancer as determined by their treating physician, according to the standard of care and routine clinical practice at each site.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women \> 18 years. * Histologically proven cervical carcinoma * Diagnosis of carcinoma of the cervix since January 2018 or newly diagnosis or recurrent disease during the period of study recruitment. * Any histology of cervical cancer at time of diagnosis. * FIGO stage IB2-IVA * Have available and adequate medical records for data collection * Accept to participate in the project and sign the informed consent (if applicable) Exclusion Criteria: * FIGO stage I and IB1 * Non-invasive cervical cancer * Synchronous tumor or second primary tumor in the last five years (exception for thyroid cancer or skin cancer non melanoma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uterine cervical neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uterine cervical neoplasms

Contacts and locations

Locations

  • BP - A Beneficência Portuguesa de São Paulo

    São Paulo, São Paulo, 01323-001, Brazil

  • CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • CRIO - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, 60335-480, Brazil

  • Centro Medico San Roque Exelsus

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Hospital Erasto Gaertner

    Curitiba, Paraná, 81520-060, Brazil

  • Hospital de Amor de Barretos

    Barretos, São Paulo, 14784-400, Brazil

  • ICESP - Instituto do Câncer do Estado de São Paulo

    São Paulo, São Paulo, 01246-000, Brazil

  • INCA - Instituto Nacional de Câncer

    Rio de Janeiro, Rio de Janeiro, 20230-130, Brazil

  • INCART - Instituto Nacional del Cáncer Rosa Emilia Sánchez Pérez de Tavares

    Santo Domingo, Grande Santo Domingo, Dominican Republic

  • Instituto Nacional de Enfermedades Neoplásicas (INEN)

    Lima, Peru, Peru

  • Pérola Centro de Pesquisa em Oncologia

    São Paulo, São Paulo, 01317-904, Brazil

  • Sanatorio de La Mujer

    Rosario, Santa Fe Province, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.